Michael Thompson, MD, PhD, Advocate Aurora Health Care, discusses social determinants of health, eligibility criteria, and other barriers to clinical trial enrollment in the community setting, as well as the importance of real-world evidence in moving the needle for oncology care.

Gilberto Lopes, MD, editor-in-chief of the Journal of Global Oncology and creator of a global oncology program at the University of Miami Sylvester Comprehensive Cancer Center, discusses the intersection of globalization and localization of cancer care and measuring success in a global oncology program, among other topics.

Gilberto Lopes, MD, editor-in-chief of the Journal of Global Oncology and creator of a global oncology program at the University of Miami Sylvester Comprehensive Cancer Center, discusses the intersection of globalization and localization of cancer care and measuring success in a global oncology program, among other topics.

Sumanta (Monty) Kumar Pal, MD, MD, GU medical oncologist at City of Hope, breaks down diagnosing and administering definitive therapy for localized muscle-invasive bladder cancer, postoperative management options for patients with residual disease, optimizing treatment decisions for metastatic disease, and more.

Sumanta (Monty) Kumar Pal, MD, MD, GU medical oncologist at City of Hope, breaks down diagnosing and administering definitive therapy for localized muscle-invasive bladder cancer, postoperative management options for patients with residual disease, optimizing treatment decisions for metastatic disease, and more.

Gary Lyman, MD, MPH, senior lead for quality and policy at the Hutchinson Institute for Cancer Outcomes Research, explains that it may take 8-12 years to prove that biosimilars should be trusted in everyday clinical practice, as well as delves into issues of granting extrapolation.

Gary Lyman, MD, MPH, senior lead for quality and policy at the Hutchinson Institute for Cancer Outcomes Research, explains that it may take 8-12 years to prove that biosimilars should be trusted in everyday clinical practice, as well as delves into issues of granting extrapolation.

Andrew Renda, MD, associate vice president of population health at Humana, discusses ways in which Humana designs supplemental benefits for social needs as well as addresses social determinants of health to close clinical gaps in care.

Andrew Renda, MD, associate vice president of population health at Humana, discusses ways in which Humana designs supplemental benefits for social needs as well as addresses social determinants of health to close clinical gaps in care.

David Fajgenbaum, MD, MBA, MSc, survivor of Castleman disease and author of "Chasing My Cure," discusses treating his own disease through experimental self-administered therapies, involvement in developing the first NCCN guidelines and FDA-approved drugs for Castleman disease, and how to effectively and systematically use off-label drugs for orphan diseases.